Dianthus Therapeutics
DNTH
84.88
-0.52
-0.61%
Dianthus Therapeutics
US · DNTH
#2155 by market cap
Listed 1970
84.88
-0.52
-0.61%
Live - 5344 symbols - heartbeat 137s ago
· 2026-10-07 21:26
After-hours
84.88
0.00%
Overnight
85.24
+0.42%
- Market cap
- 4.75B
- P/E (TTM)i
- -20.02
- P/Bi
- 4.05
- EPSi
- -4.20
- Div yieldi
- 0.00%
- 52W posi
- 61%
Reader sentiment
Are you bullish or bearish on DNTH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.2 percentage points.
Institutional ownership
- Held by institutions
- 124.60% -2.21pp
- Institutions
- 330 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund80.61%
Hedge Fund29.82%
VC/PE Fund10.46%
Public Company1.30%
Private Company0.99%
Sovereign Wealth Fund0.75%
Government Pension Fund0.36%
Insurance Company0.31%
Individual/Insider0.15%
Top holders as of 2026-06-30
FMR
14.66% · 8.20M sh
T. Rowe Price Group, Inc.
11.86% · 6.63M sh
BlackRock
7.37% · 4.12M sh
Wellington Management Group
5.77% · 3.23M sh
Fairmount Funds Management LLC
4.54% · 2.54M sh
Vanguard Capital Management, LLC
4.40% · 2.46M sh
State Street Global Advisors
4.21% · 2.36M sh
Avidity Partners Management, L.P.
3.76% · 2.10M sh
Octagon Capital Advisors LP
3.29% · 1.84M sh
TCG Crossover Management, LLC
3.00% · 1.68M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 28 buys · 22 sells
| Name | Role | Stake |
|---|---|---|
| Marino Garcia | Chief Executive Officer | 0.12% |
| Adam Veness | General Counsel | 0.03% |
| Simrat Randhawa | Chief Medical Officer | 0.01% |
| Alison Lawton | Director | -- |
| Sujay Kango | Director | -- |
| Anne McGeorge | Director | -- |
| Edward Carr | Chief Accounting Officer | -- |
| Jonathan Violin | Director | -- |
| Steven Romano | Director | -- |
| Paula Soteropoulos | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-16 | Edward Carr | Chief Accounting Officer | Derivative Exercise and Sale | -20,000 | $17.88–104.39 |
| 2026-08-31 | Simrat Randhawa | Chief Medical Officer | Derivative Exercise and Sale | -23,124 | $17.88–106.74 |
| 2026-08-18 | Simon Read | Independent Director | Derivative Exercise and Sale | -2,778 | $18.36–117.55 |
| 2026-08-12 | Adam Veness | General Counsel | Derivative Exercise and Retained | +15,000 | $18.17 |
| 2026-08-09 | Anne McGeorge | Director | Derivative Exercise and Sale | -7,750 | $11.20–111.41 |
| 2026-08-09 | Simon Read | Independent Director | Derivative Exercise and Sale | -2,777 | $18.36–111.77 |
| 2026-08-09 | Adam Veness | General Counsel | Derivative Exercise and Sale | -20,000 | $17.88–111.18 |
| 2026-08-06 | Marino Garcia | Chief Executive Officer | Derivative Exercise and Sale | -166,000 | $8.44–110.76 |
| 2026-07-08 | Ryan Savitz | Chief Financial Officer | Derivative Exercise and Sale | -31,249 | $21.77–101.97 |
| 2026-06-16 | Adam Veness | General Counsel | Derivative Exercise and Sale | -30,000 | $17.88–81.38 |
| 2026-05-31 | Simrat Randhawa | Chief Medical Officer | Derivative Exercise and Sale | -26,530 | $8.44–91.37 |
| 2026-05-20 | Alison Lawton | Director | Other Derivative Acquisition | +6,090 | $89.63 |
| 2026-05-20 | Sujay Kango | Director | Other Derivative Acquisition | +6,090 | $89.63 |
| 2026-05-20 | Anne McGeorge | Director | Other Derivative Acquisition | +6,090 | $89.63 |
| 2026-05-20 | Jonathan Violin | Director | Other Derivative Acquisition | +6,090 | $89.63 |
| 2026-05-20 | Steven Romano | Director | Other Derivative Acquisition | +6,090 | $89.63 |
| 2026-05-20 | Paula Soteropoulos | Director | Other Derivative Acquisition | +6,090 | $89.63 |
| 2026-05-20 | Simon Read | Independent Director | Other Derivative Acquisition | +6,090 | $89.63 |
| 2026-05-07 | Paula Soteropoulos | Director | Derivative Exercise and Sale | -599 | $8.44–85.47 |
| 2026-04-08 | Ryan Savitz | Chief Financial Officer | Derivative Exercise and Sale | -8,224 | $17.88–89.84 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 21:26:06 · For reference only, not investment advice and not tailored to your situation.